Envision Pharma Group announces appointment of Dr. Deepti Sodhi Jaggi to Board of Directors

Envision Pharma Group (Envision) has appointed Dr. Deepti Sodhi Jaggi to the Envision Board of Directors

“We are pleased to welcome Deepti to the Envision Board of Directors,” shares Meg Heim, CEO of Envision Pharma Group. “Deepti’s deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner.” 

Dr. Jaggi’s career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.

Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.

Dr. Jaggi’s previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.

“I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives,” says Dr. Jaggi. 

Dr. Jaggi’s educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business. 

Close

With an eye toward everyone’s health and well-being, all Envision staff will work remotely from March 23 and until further notice.

The health of everyone, from our employees and clients to our collective families and communities, remains of paramount importance to all of us at Envision Pharma Group. As such, we have implemented a phased closure of our offices globally. From Monday, March 23, the whole of Envision Pharma Group will be decentralized and working remotely until further notice.

Please rest assured:

• We will remain very much open and operational to support your ongoing and future needs
• Members of your support team already successfully operate remotely through our flexible working framework, which we are now extending across our entire organization
• You’ll continue to benefit from our experience in working with multidisciplinary teams, across multiple geographies and time zones, through video conferences and phone calls
• You can expect minimal disruption to “business as usual” with our business continuity plan. Click here to learn more

I know you will join me in thanking and appreciating the tremendous efforts of our employees, healthcare workers, communities, and governments as we work in partnership to navigate this unfolding situation.

With an eye toward your own contingency planning, please remember your Envision team is here to support you, and we are ready to answer any questions you may have. Let us know how we can help by reaching out to your EPG team contact directly, or through our contact page.

Sincerely yours,

David

Close

The PM Society Awards 2020 saw Envision pick up a gold award for Events and Exhibitions, along with two silver accolades for Interactive Communications and Innovations relating to its work in collaboration with Mundipharma.

Envision’s Mundipharma account team were joined by members of the pharma company on January 24 at The Grosvenor House in London to accept the outcome from the event judges, which even included a new category win for interactive communications.

Comments from the judges relating to the gold award noted, “It was a brave client who agreed not to show their data until delegates interacted with it, but it paid off.”

Multichannel Director at Envision Alex Watson added, “What a fantastic way for us to start the year with a triple win at the 2020 PM Society Awards. To make a real difference we believe you sometimes have to look at things from a different perspective.

“Congratulations to our exceptionally talented creative team who, in close partnership with Mundipharma and supported by woolley pau gyro, conceptualized and created this exemplar of MedComms lateral thinking that had a very real impact in getting this important message across.”

The PM Society Awards recognize creativity, impact, and innovation within communications activities in the pharmaceutical, biotechnology, and healthcare industries. The awards are unique among creative healthcare awards, in that they include categories judged by healthcare professionals – the targets of the work – as well as those judged by agency creatives and marketers.

Watson noted, “This is the second successive year that Envision has entered and won at the PM Society Awards. To have achieved this here two years in a row is testament to the talents and capabilities of our in-house team.”

Close

The Envision Pharma Group, a global technology-enabled scientific communications organization, announced today that David Thompson (right) who is currently its Chief Commercial Officer is to become the new Chief Executive Officer to coincide with the appointment of its current CEO, Brian Hepburn (left) – to the position of Executive Co-Chair for the Group. Both David and Brian will assume their new roles from January 1, 2020.

David said, “I am honored and truly excited to be taking on the role of CEO for the Envision Pharma Group. The Group has been immensely successful through its unique business model of combining strategic data-centric scientific services with best-in-class technology solutions, such as the gold standard publication planning tool, Datavision. I look forward to continuing that journey through organic growth with a focus on expanding our medical affairs value proposition via the iEnvision platform. We also plan to grow our footprint through strategic acquisitions for key adjacent services. Undoubtedly we have a unique opportunity to provide market-leading solutions (through a combination of world class services and technology enablement) to our client base – which will positively impact the effective and efficient dissemination of NCE data to HCPs, payors, and patients alike.”

David joined the organization as part of Envision’s acquisition of Alligent Biopharm Consulting LLC, in September of 2015. Since then David has been instrumental in expanding the Group’s multichannel medical communication capabilities, fully aligning with the medical strategy and data dissemination core competences of Envision. He will continue to drive Envision’s goal of being seen as a strategic partner of choice for the medical affairs function within our biopharmaceutical and medical device client base. David is a 24-year veteran of the pharma services industry, having spent 15 of those years in the United States. In this role he will be based out of our UK, Horsham offices.

Brian, founder CEO from 2001, will continue to provide strategic direction and management support for the Group. He will maintain an active role driving the culture and company ethos for the ever-expanding team – which to date has been instrumental in creating one of the world’s preeminent medical affairs-focused outsourced pharma technology and services organizations.

“I can think of no one better to take over the mantle of the CEO for the Group,” added Brian. “David has been with the organization for 4 years now and truly understands its DNA, which is often the biggest challenge for any incoming CEO. In addition, he brings an energy and ‘can-do’ attitude to the table which will ensure we continue to innovate and challenge the norm. This planned transition has been in the making for some time now and I look forward to working with him closely on this new phase of the journey for Envision.”

Close

Starting at the beginning, being able to spot the key warning signs of diabetes can be paramount for early diagnosis and treatment. However, half the people living with diabetes are doing so unknowingly. For this reason, the International Diabetes Federation wants to escalate the awareness of diabetes by educating the public. The hope is that this will increase recognition of warning signs and early treatment, and reduce the risks of long-term health complications. Diabetes requires constant management, ranging from daily medication and monitoring, to application of a healthy lifestyle – so having the support of family and friends is key.

This year the main theme for World Diabetes Day is family and diabetes, raising the awareness of the impact it can have on those around you.

Close

Envision has announced another office relocation for 2019, this time in West London. Situated just steps away from Hammersmith tube station, the new office will be home to an expanding group of talented Envision employees spanning disciplines in medical writing, HEOR and market access consulting, creative, account management and operations.

Global Business Unit Head Kristyn Morgan said, “With views over West London, a roof terrace and a dynamic working environment, we are thrilled to announce the opening of our newest office. 2019 has certainly been a year for Envision growth and office expansion, and we see 2020 looking no different. Our new Hammersmith location now has the appropriate space to accommodate our team, and the energy to attract incremental talent and skills to meet our pharmaceutical client’s evolving needs!”

This is the latest in a number of office announcements by Envision Pharma Group. Earlier this year Envision saw significant office expansion for both its Horsham and Wilmslow offices in the UK, and the relocation and expansion of two of its East Coast offices in the US. With an office opening now planned in Szeged, Hungary before 2020 – the rapid pace of growth for Envision continues.

Close

Every year, Envision Pharma Group holds a Medical Affairs (MA) Round Table meeting to bring together industry leaders and discuss current topics within MA. This year, approximately 15 attendees met in New York City to discuss industry best practices, understand common challenges that often arise – and have the opportunity to network with other industry leaders. The annual meeting helps to focus on, and discuss, important and valuable topics within our industry together. Past topics have included:

Past topic have included:

• Global Alignment in Medical Affairs
• Patient Engagement: Real-World Evidence
• Insights Identification
• Automation & Organizational Efficiencies
• Medical Affairs Metrics
• Thought-Leader Engagement
• Demonstrating the Value of Medical Affairs
• Maximizing Data Roll-Out

The outcomes from this year’s annual round table helped further Envision’s perspective surrounding the current landscape of our industry, and up and coming trends. Along with general industry research, stakeholder interviews, as well as the conversations had with this year’s attendees, the Envision team put together the Medical Affairs 5-year Landscape Analysis. This focuses on the major trends influencing MA and identifies the key findings. Additionally, the team was able to detect some of the major impacts each trend will have upon the industry, based on the information obtained from the research and stakeholder interviews.

Click here for a look at our interactive Landscape Analysis infographic inclusive of the 8 trends and the potential influence they could have on the Medical Affairs industry.

If you would like more information regarding the next Envision Pharma Group Medical Affairs Round Table, please get in touch: EPGRoundtable@Envisionpharmagroup.com

Close

Fuelled by continued growth in its technology solutions unit, Envision Pharma Group is opening a new office in Szeged, Hungary.

Peter Jankovics, Product Development, Technology Solutions said, “It is exciting that we can expand Envision’s presence in Central Europe by opening a modern and stylish office in the center of the beautiful city of Szeged, Hungary. This office will certainly help us to reach more people who could experience the rewarding work environment and culture Envision represents.”

Envision plans to open the doors by the end of year, and in the meantime continues to look for talented individuals interested in working in a global technology environment within the healthcare industry.

For more information on the technology opportunities we have available, contact opportunities-US@EnvisionPharmaGroup.com

Close

Envision has won gold and silver excellence awards for its work in collaboration with Mundipharma at the 10th anniversary of the PM Society Digital Awards.

The Mundipharma account team from Envision headed up to The Brewery, London on the 19th September to attend and await the outcome from the judges.

In recognition for its unique approach to digital creativity, the team scooped one Gold award for ‘Excellence in Congress, Meetings and Events’, along with a Silver for ‘Innovation – Creativity’.

Awards judge and Medical Director Joubert Gama said, “The team were really impressed with this entry, especially in terms of keeping with the theme of the congress which was sustainability. The technology was really well used and the insights gained from different customers were used to guide them for future materials.”

Multichannel Director at Envision Alex Watson added, “Envision Pharma Group are thrilled to have won both of these aspirational PM Society Digital Awards for our work in collaboration with Mundipharma.”

“Bringing physical and tangible interactions to the unbound value of digital communication channels is not only a recipe for communication success for both us and our clients, but more importantly also for healthcare professionals who see real value in having information personalised to their interests and delivered in engaging and memorable ways.”

Now in its 10th year, the PM Society Digital Awards strive to recognise digital effectiveness, creativity and innovation within the healthcare industry – highlighting programmes, tools and campaigns across a range of digital activities.”

There are 15 categories that are all judged over a two-stage process, with many of the judges working within the healthcare industry themselves, who are assisted by creative and digital experts.

Watson noted, “This is the first time Envision have entered the PM Society Digital Awards so to have achieved this accolade is testament to the talents and capabilities of our in-house team. Congratulations to all involved, and thank you Mundipharma for the opportunity.”

Close

Prompted by significant growth, the relocation from its Southport, CT office in August allows for continued company expansion amongst state of the art, modern surroundings. One of the many investments made at this new location is The Lab – an innovation space where teams and clients can immerse themselves and play with the latest technologies enhancing healthcare communications.

Envision Scientific Solutions Global Lead Susanne Clark said, “We’ve moved our Southport office location into this new custom remodeled office area. We are thrilled to be able to continue to grow together in our new space!

“This location provides greater opportunities for our teams to share ideas and collaborate together. The updates we’ve made have created a high tech, connected workspace that will benefit both our existing and future global medical affairs clients. We look forward to welcoming clients into our innovation Lab.”

With a new office opening in Warren, NJ , significant office expansion earlier this year in Horsham and Wilmslow, UK along with recent award successes – 2019 is proving to be an exciting time for the business, clients, and new talent in the medical affairs arena.

Close

Envision has moved its Stirling and Madison offices to a larger combined office location in Warren, NJ. With a collaborative working space and scope for significant team expansion, this new site strengthens and serves as a long-term commitment to East Coast employees and brings Envision even closer to its clients.

Envision Global Business Unit Head Todd Courcy said, “The Warren office is home to staff supporting multiple services, and will continue to be a recruitment hub in the US to support our growth.

“The space showcases state of the art conference rooms, kitchen, offices, work stations, and IT infrastructure. Not to mention the amazing coffee and cappuccino machine!”

With a new office opening in Fairfield, CT, significant office expansion earlier this year in Horsham and Wilmslow, UK along with recent award successes – 2019 is proving to be an exciting time for the business, clients, and new talent in the medical affairs arena.

Close

Envision Pharma Group and the Ectodermal Dysplasia (ED) Society have won the award for “Writing Excellence” at the Communiqué Awards in London’s Park Lane.

The accreditation programme was designed to recognise and commend excellence and best practice in European, international and local healthcare communications – and has praised Envision’s collaboration with the charity, which resulted in a patient information book aimed at children to raise awareness and support around the rare genetic disorder.

“Everybody’s different: An introduction to Ectodermal Dysplasia” was designed for children aged 4+, with and without ED, and allows parents and schools to explain the condition in child-friendly terms. It facilitates empathy and gives children the ideas and motivation to then help their peers.

Speaking at the event was Diana Perry, who is the chief executive of the ED Society, “We are thrilled to have won the Writing Excellence award at the Communiqué Awards tonight in London for our book ‘Everybody’s Different’. We are forever grateful to Envision Pharma Group who helped us to develop the book.”

David Thompson who is the Chief Commercial Officer at Envision, added, “It was a wonderful achievement for the team to be recognised for writing excellence at the industry’s Communiqué awards. To partner with the ED Society and have Diana Perry present to pick up the award was a privilege for us all.

“Most importantly, we maintain real belief and hope that the ‘Everybody’s different’ book aimed at children, can continue to make a real difference for this rare disease patient community.”

Click here for a video and summary from the event hosts, and to see what the judges had to say. To access a copy of the patient information material, click here, and for more information regarding Envision's patient work follow this link.

Close